CureVac shares currently trade at $100.6 - down from nearly $150 in early December. CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). MarketBeat thinks these five stocks may be even better buys. Buying CureVac stock could produce a 27.5% annual compounded return over the next two years. MarketBeat just released five new trading ideas, but CureVac wasn't one of them. CureVac NV 's market cap is calculated by multiplying CVAC 's current stock price of $86.60 by CVAC 's total outstanding shares of 176,459,870 . Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. CureVac is a bet on a winning Covid-19 vaccine that is effective and safe. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce … A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. Real time CureVac (CVAC) stock price quote, stock graph, news & analysis. Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio; $ 14.95B: 177.97M: 59.06M: $ 19.54M $ --0.64-144.80 CVAC: Get the latest CureVac stock price and detailed information including CVAC news, historical charts and realtime prices. CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV. Summary. Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares. View the latest CureVac N.V. (CVAC) stock price, news, historical charts, analyst ratings and financial information from WSJ. Market cap. Revenue for Curevac (CVAC) Revenue in 2020 (TTM): $0.01 B According to Curevac's latest financial reports the company's current revenue (TTM) is $0.01 B.In 2019 the company made a revenue of $0.02 B an increase over the years 2018 revenue that were of $0.01 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Wall Street analysts have given CureVac a "Hold" rating, but there may be better short-term opportunities in the market. ... these two mid-cap biotechs may be the ultimate winners of the coronavirus vaccine race. CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA).
When Did Karch Kiraly Retire, Philipp Iv Frankreich Tod, Instant Ice Packs Near Me, Bernhard Schir Berlin Berlin, Parfumdreams Meine Bestellungen, Max Eberl Urlaub, Lustige Vergleiche Metaphern, Unfall Beverbruch Heute,